Here, we studied the feasibility and immunogenicity to treat patients with platinum-resistant p53-positive ovarian cancer using combinatorial regimens in which p53 SLP vaccination and Pegintron (IFN-α) were administrated before and after the first cycle of gemcitabine. The gene discussed is IFNA2; the disease is ovarian carcinoma.